Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma
February 15, 2001
Is there an advantage of IP cisplatin over IV cisplatin after optimally debulked ovarian cancer?
Cisplatin 75 mg/m2 IV
paclitaxel 135 mg/m2 IV
q3 wkc x6 cycles
Carboplatin (AUC 9) IV q4 wks x 2 cycles
Cisplatin 100 mg/m2 IP + paclitaxel 135 mg/m2 IV over 24hrs q3 weeks x 6 cycles
OS
Epithelial ovarian cancer
Stage III
Optimal debulking
Borderline
Prior chemo/radiation
IP vs IV:
median PFS: 27.9 vs 22.2 months (SS)
median OS: 63.2 vs 52.2 months (p=0.05)
G4 neutropenia: 28% vs 13%
G4 thrombocytopenia: 24% vs 1%
G4 GI: 20% vs 8%
There is a PFS advantage associated with the use of IP cisplatin compared with IV cisplatin for stage III epithelial ovarian cancer, after optimal debulking.